BACKGROUND: Vectors derived from alphaviruses are gaining interest for their high transfection potency and strong immunogenicity. OBJECTIVES: After a brief introduction on alphaviruses and their vectors, an overview is given on current preclinical immunotherapy studies using vector systems based on alphaviruses. The efficacy of alphavirus vectors in inducing immune responses will be illustrated by a more detailed description of immunization studies using recombinant Semliki Forest virus for the treatment of human papilloma virus-induced cervical cancer. RESULTS: Immunization with recombinant alphavirus results in the induction of humoral and cellular immune responses against microbes, infected cells and cancer cells. Preclinical studies demonstrate that infectious diseases and cancer can be treated prophylactically as well as therapeutically. CONCLUSIONS: Alphavirus-based genetic immunization strategies are highly effective in animal model systems, comparing quite favourably with any other approach. Therefore, we hope and expect to see an efficient induction of tumour-or microbial immunity and a positive outcome in future clinical efficacy studies.
BACKGROUND: Vectors derived from alphaviruses are gaining interest for their high transfection potency and strong immunogenicity. OBJECTIVES: After a brief introduction on alphaviruses and their vectors, an overview is given on current preclinical immunotherapy studies using vector systems based on alphaviruses. The efficacy of alphavirus vectors in inducing immune responses will be illustrated by a more detailed description of immunization studies using recombinant Semliki Forest virus for the treatment of human papilloma virus-induced cervical cancer. RESULTS: Immunization with recombinant alphavirus results in the induction of humoral and cellular immune responses against microbes, infected cells and cancer cells. Preclinical studies demonstrate that infectious diseases and cancer can be treated prophylactically as well as therapeutically. CONCLUSIONS: Alphavirus-based genetic immunization strategies are highly effective in animal model systems, comparing quite favourably with any other approach. Therefore, we hope and expect to see an efficient induction of tumour-or microbial immunity and a positive outcome in future clinical efficacy studies.
Authors: Jelena Vasilevska; Gustavo Antonio De Souza; Maria Stensland; Dace Skrastina; Dmitry Zhulenvovs; Raimonds Paplausks; Baiba Kurena; Tatjana Kozlovska; Anna Zajakina Journal: Cancer Biol Ther Date: 2016-09-16 Impact factor: 4.742
Authors: María Q Marín; Patricia Pérez; Karl Ljungberg; Carlos Óscar S Sorzano; Carmen E Gómez; Peter Liljeström; Mariano Esteban; Juan García-Arriaza Journal: J Virol Date: 2019-03-21 Impact factor: 5.103
Authors: Debasis Panda; Patrick P Rose; Sheri L Hanna; Beth Gold; Kaycie C Hopkins; Randolph B Lyde; Michael S Marks; Sara Cherry Journal: Cell Rep Date: 2013-12-12 Impact factor: 9.423
Authors: Francesca Avogadri; Roberta Zappasodi; Arvin Yang; Sadna Budhu; Nicole Malandro; Daniel Hirschhorn-Cymerman; Shakuntala Tiwari; Maureen F Maughan; Robert Olmsted; Jedd D Wolchok; Taha Merghoub Journal: Cancer Immunol Res Date: 2014-02-26 Impact factor: 11.151
Authors: Francesca Avogadri; Taha Merghoub; Maureen F Maughan; Daniel Hirschhorn-Cymerman; John Morris; Erika Ritter; Robert Olmsted; Alan N Houghton; Jedd D Wolchok Journal: PLoS One Date: 2010-09-10 Impact factor: 3.240
Authors: D A Shilling; M J Smith; R Tyther; D Sheehan; K England; E G Kavanagh; H P Redmond; F Shanahan; L O'Mahony Journal: Clin Exp Immunol Date: 2007-04-25 Impact factor: 4.330